Please login to the form below

Not currently logged in
Email:
Password:

Acino

This page shows the latest Acino news and features for those working in and with pharma, biotech and healthcare.

Oncology bias in pharma deals

Regorafenib is in phase III. 160. Cephalon/Acino. Regional business acquisition. Generics.

Latest news

More from news
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Deal Watch table for October 2013 Deal Watch table for October 2013

    440. Acino / Avista Capital and Nordic Capital. Acquisition. Portfolio of drug delivery products (marketed).

  • Pharma deals during October 2013 Pharma deals during October 2013

    The other major deal featuring PE is the acquisition of Acino by Avista Capital Partners and Nordic Capital for $439m. ... share. The sale has been strongly supported by the Acino Board, notably the stock had fallen by 62 per cent over the last five years

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics